Zacks Investment Research upgraded shares of Fresenius Medical Care Corporation (NYSE:FMS) from a hold rating to a buy rating in a report released on Tuesday morning. Zacks Investment Research currently has $54.00 price target on the stock.

According to Zacks, “Fresenius Medical Care has set up a strong long term objective called the ‘Growth Strategy 2020’, where it aims to increase its revenue to $28 billion by 2020, corresponding to an average annual growth rate of around 10%. Fresenius Medical Care reported a solid first quarter of 2017, beating the Zacks Consensus Estimate for both top line and bottom line. Furthermore, an upbeat guidance instills our confidence on the company’s stock. A wide range of dialysis products, deliberate initiatives for attaining market traction, solid international foothold, strategic acquisitions & divestments are major growth catalysts for the company at the moment. However, Fresenius Medical Care stock looks overvalued at the moment. Apart from this, the company has had a disappointing run on the bourse over the last one year. A tough regulatory environment, difficulties in attaining a solid profit margin in foreign legal-paradigms & competition in the niche markets are headwinds.”

A number of other analysts have also recently weighed in on FMS. Nord/LB reaffirmed a buy rating on shares of Fresenius Medical Care Corporation in a research report on Wednesday, June 28th. Royal Bank Of Canada reaffirmed a hold rating and issued a $44.00 price target on shares of Fresenius Medical Care Corporation in a research report on Tuesday, May 30th. DZ Bank AG reaffirmed a neutral rating on shares of Fresenius Medical Care Corporation in a research report on Monday, May 29th. Finally, UBS AG reaffirmed a sell rating on shares of Fresenius Medical Care Corporation in a research report on Tuesday, July 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $48.67.

Fresenius Medical Care Corporation (NYSE:FMS) traded down 0.28% during trading on Tuesday, hitting $49.16. The stock had a trading volume of 54,372 shares. The firm’s 50 day moving average is $47.75 and its 200 day moving average is $43.48. The firm has a market cap of $30.12 billion, a price-to-earnings ratio of 20.98 and a beta of 0.48. Fresenius Medical Care Corporation has a 1-year low of $38.05 and a 1-year high of $50.22.

Fresenius Medical Care Corporation (NYSE:FMS) last issued its earnings results on Wednesday, May 3rd. The company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.09. Fresenius Medical Care Corporation had a return on equity of 11.79% and a net margin of 7.24%. The firm had revenue of $4.55 billion for the quarter, compared to the consensus estimate of $4.69 billion. During the same quarter in the previous year, the company posted $0.75 earnings per share. On average, analysts anticipate that Fresenius Medical Care Corporation will post $2.28 earnings per share for the current year.

WARNING: “Zacks Investment Research Upgrades Fresenius Medical Care Corporation (FMS) to “Buy”” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/07/17/zacks-investment-research-upgrades-fresenius-medical-care-corporation-fms-to-buy.html.

A number of institutional investors have recently bought and sold shares of the stock. Level Four Advisory Services LLC boosted its position in Fresenius Medical Care Corporation by 0.5% in the first quarter. Level Four Advisory Services LLC now owns 11,434 shares of the company’s stock valued at $478,000 after buying an additional 58 shares during the period. Intrust Bank NA boosted its position in Fresenius Medical Care Corporation by 0.8% in the first quarter. Intrust Bank NA now owns 13,219 shares of the company’s stock valued at $557,000 after buying an additional 99 shares during the period. Wrapmanager Inc. boosted its position in Fresenius Medical Care Corporation by 3.5% in the first quarter. Wrapmanager Inc. now owns 7,222 shares of the company’s stock valued at $304,000 after buying an additional 244 shares during the period. World Asset Management Inc boosted its position in Fresenius Medical Care Corporation by 1.0% in the first quarter. World Asset Management Inc now owns 38,273 shares of the company’s stock valued at $1,612,000 after buying an additional 369 shares during the period. Finally, Quadrant Capital Group LLC boosted its position in Fresenius Medical Care Corporation by 12.7% in the first quarter. Quadrant Capital Group LLC now owns 3,736 shares of the company’s stock valued at $149,000 after buying an additional 420 shares during the period. 2.83% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Get a free copy of the Zacks research report on Fresenius Medical Care Corporation (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Stock Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related stocks with our FREE daily email newsletter.